1. Home
  2. JSPR vs ACCS Comparison

JSPR vs ACCS Comparison

Compare JSPR & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JSPR
  • ACCS
  • Stock Information
  • Founded
  • JSPR 2018
  • ACCS 1988
  • Country
  • JSPR United States
  • ACCS United States
  • Employees
  • JSPR N/A
  • ACCS N/A
  • Industry
  • JSPR Biotechnology: Biological Products (No Diagnostic Substances)
  • ACCS Publishing
  • Sector
  • JSPR Health Care
  • ACCS Consumer Discretionary
  • Exchange
  • JSPR Nasdaq
  • ACCS Nasdaq
  • Market Cap
  • JSPR 47.6M
  • ACCS 42.6M
  • IPO Year
  • JSPR N/A
  • ACCS N/A
  • Fundamental
  • Price
  • JSPR $2.45
  • ACCS $9.96
  • Analyst Decision
  • JSPR Buy
  • ACCS Strong Buy
  • Analyst Count
  • JSPR 11
  • ACCS 1
  • Target Price
  • JSPR $28.00
  • ACCS $14.00
  • AVG Volume (30 Days)
  • JSPR 439.0K
  • ACCS 6.1K
  • Earning Date
  • JSPR 11-06-2025
  • ACCS 11-06-2025
  • Dividend Yield
  • JSPR N/A
  • ACCS N/A
  • EPS Growth
  • JSPR N/A
  • ACCS N/A
  • EPS
  • JSPR N/A
  • ACCS N/A
  • Revenue
  • JSPR N/A
  • ACCS $22,562,000.00
  • Revenue This Year
  • JSPR N/A
  • ACCS $0.03
  • Revenue Next Year
  • JSPR N/A
  • ACCS $11.45
  • P/E Ratio
  • JSPR N/A
  • ACCS N/A
  • Revenue Growth
  • JSPR N/A
  • ACCS 26.44
  • 52 Week Low
  • JSPR $2.22
  • ACCS $7.79
  • 52 Week High
  • JSPR $26.05
  • ACCS $13.35
  • Technical
  • Relative Strength Index (RSI)
  • JSPR 46.88
  • ACCS 37.73
  • Support Level
  • JSPR $2.33
  • ACCS $9.51
  • Resistance Level
  • JSPR $2.65
  • ACCS $10.90
  • Average True Range (ATR)
  • JSPR 0.15
  • ACCS 0.31
  • MACD
  • JSPR 0.03
  • ACCS -0.05
  • Stochastic Oscillator
  • JSPR 53.32
  • ACCS 32.37

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About ACCS ACCESS Newswire Inc.

ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.

Share on Social Networks: